Opinion

Video

Candidates for Oral JAK Inhibitor Use in Atopic Dermatitis

An expert on atopic dermatitis identifies patients who are good candidates for JAK inhibitors, highlighting contraindications for treatment.

Video content above is prompted by the following questions:

  • Who is/is not a good candidate for JAK inhibitor?
    • What findings would you consider to be absolute or relative contraindications for JAK inhibitor use in AD?
Related Videos
Discussing FDA Approval of Tapinarof Cream for Atopic Dermatitis, with John Browning, MD
Discussing 140-Week Data on Upadacitinib for Atopic Dermatitis, with Raj Chovatiya, MD, PhD
ADORING Trial Open-Label Extension: Tapinarof Cream 1% Results in Atopic Dermatitis
Linda Stein Gold, MD: Discussing New Phase 3b Data on Lebrikizumab for Atopic Dermatitis
New ‘Level Up’ Data on Upadacitinib (Rinvoq) for Atopic Dermatitis, with Christopher Bunick, MD, PhD
Shawn Kwatra, MD: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch
© 2024 MJH Life Sciences

All rights reserved.